Completed PHASE2 INTERVENTIONAL NCT00255281

Efficacy and Safety of AZD7009 in the Treatment of Atrial Fibrillation

A Double-Blind, Randomised, Placebo-Controlled, Parallel-Group, Multicentre, Phase II Study to Assess the Efficacy of AZD7009 (AR H065522XX) Given Intravenously (Infusion for 15 or 30 Minutes) to Patients for Conversion of Atrial Fibrillation

Sponsor: AstraZeneca

Conditions Atrial Fibrillation

Interventions AZD7009, no generic name available

Updated 6 times since 2017 Last updated: Dec 4, 2007 Started: Sep 30, 2005 Completion: May 31, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00255281, this PHASE2 trial focuses on Atrial Fibrillation and remains completed. Sponsored by AstraZeneca, it has been updated 6 times since 2005, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Sep 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AstraZeneca

Data source: AstraZeneca

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aachen, Germany , Bad Berka, Germany , Brandenburg, Germany , Budapest, Hungary , Bytom, Poland , Cegléd, Hungary , Esbjerg, Denmark , Groningen, Netherlands , Hamburg, Germany , Hellerup, Denmark and 22 more locations